Abvc Biopharma Inc Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
* ABVC Biopharma Inc ABVC.OQ ABVC.O is expected to show
a fall
in quarterly revenue when it reports results on May 15
(estimated).
*
* Refinitiv's mean analyst estimate for ABVC Biopharma Inc
is for
a loss of 5 cents per share.
* The one available analyst rating on the shares is
"hold".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for ABVC
Biopharma
Inc is $2.02, above its last closing price of $0.78.
This summary was machine generated May 12 at 11:52 GMT. All
figures in US dollars unless otherwise stated
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner